Press Release Archives
Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc. engages in developing products at the intersection of drugs and devices. Its products are using in the treatment of cardiopulmonary and cardiac diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

Bellerophon Therapeutics Inc Press Releases

Press Archives

Bellerophon Therapeutics Inc

Press Archives

Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

Apr 8th 2020

IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Apr 6th 2020

Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

Apr 1st 2020

Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

Mar 31st 2020

Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

Mar 30th 2020

Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

Mar 30th 2020

FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus

Mar 20th 2020

Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

Mar 10th 2020

Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

Feb 18th 2020

Bellerophon Announces 1-for-15 Reverse Stock Split

Feb 7th 2020

Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Dec 17th 2019

Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Nov 12th 2019